asa glp-1 agonist guidelines Perioperative management of patients on receptor agonists: Risks, recommendations, and future directions—A narrative review GLP-1 and Anesthesia: Considerations and

J Inflammation Res (2021) 14:227787

This helps you feel fuller for longer, reduces cravings, and supports sustainable weight loss

Further research is needed to explore the full therapeutic potential and long-term safety of GLP-1RAs across a broader range of metabolic and neurodegenerative disorders

On the basis of results of the most recent CVOTs (DAPA-HF, DAPA-CKD, EMPEROR-R), the FDA has approved dapagliflozin (2020) and empagliflozin (2021) to reduce risk for CV death and HF hospitalization in adults with HF and reduced ejection fraction regardless of whether they have diabetes [24, 25]

Given the established cardiovascular and kidney benefits of SGLT2is for T2DM patients with CVDs, those at high risk, and those with CKD, along with recent cohort studies demonstrating their ability to enhance survival, reduce cardiovascular events, and preserve graft function in kidney KTRs with DM, we conducted additional analyses incorporating SGLT2is [38,39,40,41,42]